Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,711
archived clinical trials in
Depression

To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site #028
mi
from
Norristown, PA
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site #028
mi
from
Norristown, PA
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site
mi
from
Lincoln, RI
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site
mi
from
Lincoln, RI
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site 001
mi
from
North Charleston, SC
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site 001
mi
from
North Charleston, SC
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site
mi
from
Houston, TX
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site
mi
from
Houston, TX
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site 082
mi
from
Wichita Falls, TX
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site 082
mi
from
Wichita Falls, TX
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site 111
mi
from
Murray, UT
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site 111
mi
from
Murray, UT
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site 064
mi
from
Charlottesville, VA
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site 064
mi
from
Charlottesville, VA
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site 014
mi
from
Bothell, WA
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site 014
mi
from
Bothell, WA
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site #027
mi
from
Seattle, WA
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site #027
mi
from
Seattle, WA
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site 007
mi
from
Middleton, WI
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site 007
mi
from
Middleton, WI
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site 049
mi
from
Milwaukee, WI
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site 049
mi
from
Milwaukee, WI
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site 057
mi
from
Waukesha, WI
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site 057
mi
from
Waukesha, WI
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site #021
mi
from
Garden Grove, CA
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site #021
mi
from
Garden Grove, CA
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site 008
mi
from
Redlands, CA
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site 008
mi
from
Redlands, CA
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site 1854
mi
from
Hialeah, FL
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site 1854
mi
from
Hialeah, FL
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site #005
mi
from
North Miami, FL
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site #005
mi
from
North Miami, FL
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site 004
mi
from
Overland Park, KA
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site 004
mi
from
Overland Park, KA
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site 066
mi
from
Mason, OH
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site 066
mi
from
Mason, OH
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site 064
mi
from
Middleburg Heights, OH
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site 064
mi
from
Middleburg Heights, OH
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site 014
mi
from
Austin, TX
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site 014
mi
from
Austin, TX
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site
mi
from
Bellevue, WA
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site
mi
from
Bellevue, WA
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site 033
mi
from
San Juan,
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site 033
mi
from
San Juan,
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site #015
mi
from
Fort Myers, FL
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site #015
mi
from
Fort Myers, FL
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site 066
mi
from
Smyrna, GA
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site 066
mi
from
Smyrna, GA
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site 086
mi
from
Saint Charles, MO
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site 086
mi
from
Saint Charles, MO
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site
mi
from
Albuquerque, NM
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site
mi
from
Albuquerque, NM
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site 020
mi
from
Bismarck, ND
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site 020
mi
from
Bismarck, ND
Click here to add this to my saved trials
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated:  3/8/2018
Forest Investigative Site 045
mi
from
The Woodlands, TX
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
Status: Enrolling
Updated: 3/8/2018
Forest Investigative Site 045
mi
from
The Woodlands, TX
Click here to add this to my saved trials
Daily Weight Feedback for Wheelchair Users to Promote Weight Loss
Daily Self-weighing Feedback for Wheelchair Users to Promote Weight Loss Through Use of the E-scale
Status: Enrolling
Updated:  3/9/2018
University of Pittsburgh
mi
from
Pittsburgh, PA
Daily Weight Feedback for Wheelchair Users to Promote Weight Loss
Daily Self-weighing Feedback for Wheelchair Users to Promote Weight Loss Through Use of the E-scale
Status: Enrolling
Updated: 3/9/2018
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Brain Imaging of rTMS Treatment for Depression
A Causal Neural Network-level Understanding of Depression and Its Treatment Through Concurrent TMS and fMRI
Status: Enrolling
Updated:  3/10/2018
Stanford University
mi
from
Palo Alto, CA
Brain Imaging of rTMS Treatment for Depression
A Causal Neural Network-level Understanding of Depression and Its Treatment Through Concurrent TMS and fMRI
Status: Enrolling
Updated: 3/10/2018
Stanford University
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Beat the Blues in Pregnancy Study - Transcranial Magnetic Stimulation
Transcranial Magnetic Stimulation (TMS) in Pregnant Women With Depressive Disorder
Status: Enrolling
Updated:  3/14/2018
Penn Center for Women's Behavioral Wellness
mi
from
Philadelphia, PA
Beat the Blues in Pregnancy Study - Transcranial Magnetic Stimulation
Transcranial Magnetic Stimulation (TMS) in Pregnant Women With Depressive Disorder
Status: Enrolling
Updated: 3/14/2018
Penn Center for Women's Behavioral Wellness
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Genecept Assay and Adverse Effects of Antidepressants
Genecept Assay and Adverse Effects of Antidepressants
Status: Enrolling
Updated:  3/14/2018
Thomas Jefferson University
mi
from
Philadelphia, PA
Genecept Assay and Adverse Effects of Antidepressants
Genecept Assay and Adverse Effects of Antidepressants
Status: Enrolling
Updated: 3/14/2018
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Depression and ART Adherence in HIV+ Latinos
Addressing Depression and ART Adherence in HIV+ Latinos on the U.S.-Mexico Border
Status: Enrolling
Updated:  3/15/2018
Centro de Salud Familiar La Fe CARE Center
mi
from
El Paso, TX
Depression and ART Adherence in HIV+ Latinos
Addressing Depression and ART Adherence in HIV+ Latinos on the U.S.-Mexico Border
Status: Enrolling
Updated: 3/15/2018
Centro de Salud Familiar La Fe CARE Center
mi
from
El Paso, TX
Click here to add this to my saved trials
Improving Patient and Family Centered Care in Advanced Critical Illness
Improving Patient and Family Centered Care in Advanced Critical Illness
Status: Enrolling
Updated:  3/16/2018
University of Pittsburgh Medical Centers
mi
from
Pittsburgh, PA
Improving Patient and Family Centered Care in Advanced Critical Illness
Improving Patient and Family Centered Care in Advanced Critical Illness
Status: Enrolling
Updated: 3/16/2018
University of Pittsburgh Medical Centers
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated:  3/16/2018
Clinical Research Facility
mi
from
Birmingham, AL
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated: 3/16/2018
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated:  3/16/2018
Clinical Research Facility
mi
from
Little Rock, AR
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated: 3/16/2018
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated:  3/16/2018
Clinical Research Facility
mi
from
Beverly Hills, CA
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated: 3/16/2018
Clinical Research Facility
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated:  3/16/2018
Clinical Research Facility
mi
from
Cerritos, CA
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated: 3/16/2018
Clinical Research Facility
mi
from
Cerritos, CA
Click here to add this to my saved trials
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated:  3/16/2018
Clinical Research Facility
mi
from
Denver, CO
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated: 3/16/2018
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated:  3/16/2018
Clinical Research Facility
mi
from
Hamden, CT
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated: 3/16/2018
Clinical Research Facility
mi
from
Hamden, CT
Click here to add this to my saved trials
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated:  3/16/2018
Clinical Research Facility
mi
from
North Miami, FL
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated: 3/16/2018
Clinical Research Facility
mi
from
North Miami, FL
Click here to add this to my saved trials
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated:  3/16/2018
Clinical Research Facility
mi
from
Orlando, FL
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated: 3/16/2018
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated:  3/16/2018
Clinical Research Facility
mi
from
West Palm Beach, FL
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated: 3/16/2018
Clinical Research Facility
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated:  3/16/2018
Clinical Research Facility
mi
from
Atlanta, GA
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated: 3/16/2018
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated:  3/16/2018
Clinical Research Facility
mi
from
Smyrna, GA
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated: 3/16/2018
Clinical Research Facility
mi
from
Smyrna, GA
Click here to add this to my saved trials
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated:  3/16/2018
Clinical Research Facility
mi
from
Overland Park, KA
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated: 3/16/2018
Clinical Research Facility
mi
from
Overland Park, KA
Click here to add this to my saved trials
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated:  3/16/2018
Clinical Research Facility
mi
from
Baltimore, MD
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated: 3/16/2018
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated:  3/16/2018
Clinical Research Facility
mi
from
Willingboro, NJ
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated: 3/16/2018
Clinical Research Facility
mi
from
Willingboro, NJ
Click here to add this to my saved trials
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated:  3/16/2018
Clinical Research Facility
mi
from
Albuquerque, NM
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated: 3/16/2018
Clinical Research Facility
mi
from
Albuquerque, NM
Click here to add this to my saved trials
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated:  3/16/2018
Clinical Research Facility
mi
from
Portland, OR
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Status: Enrolling
Updated: 3/16/2018
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials